EGFR and central nervous system cancer: In the 2016 and 2021 revised WHO classification of central nervous system tumors, IDH1/2 status, 1p/19q, telomerase reverse transcriptase (TERT), epidermal growth factor receptor (EGFR) and human tumor protein p53 (TP53) were recommended for use in gliomas diagnosis and classification [2, 5].